| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Oscar Health, Inc.
$32.04
+0.45 (+1.43%)
Market Cap
8.76 B
EPS
1.78
P/E Ratio
17.96 $
Value Trade
184.38 M
1.55 %
Week
13.06 %
1 Month
46.37 %
3 Month
157.35 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
5.36 M
52 Week Range
10.69 - 33.48
% held by Insiders
18.58 %
% held by Institutions
61.55 %
Enterprise Value
-962.71 M
Total Shares
273.47 M
Short %
7.58 %
Float Shares
235.27 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OSCR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OSCR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-09-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-OSCR
Aug 6, 2026▼ -11.9%on this news
Oscar Health Announces Record Financial Results for First Half 2026 and Raises Full Year 2026 Outlook
Oscar Health reported strong financial results for the second quarter of 2026, showcasing significant improvements compared to the previous year. The company has raised its outlook for the full year 2026, indicating confidence in continued growth. All core metrics demonstrated positive trends, reflecting the company's robust performance.
Read more →-OSCR
Jul 28, 2026▲ +10.8%on this news
Oscar Health, Inc. to Host 2026 Investor Day
Oscar Health, Inc. has announced that it will host its 2026 Investor Day on September 16, 2026. This event aims to provide insights and updates to investors about the company's future strategies and performance. The early announcement reflects the company's commitment to investor relations.
Read more →-OSCR
Jul 13, 2026Oscar Health, Inc. 2026 Second Quarter Earnings Conference Call
Oscar Health, Inc. is set to announce its financial results for the second quarter of 2026 on August 6, 2026. This release is part of the company's regular reporting schedule. Investors and analysts will be keen to assess the company's performance during this period.
Read more →-OSCR
Apr 20, 2026Meet Lucie. A New Way to Shop for Healthcare.
The article introduces a new healthcare shopping platform named Lucie. It emphasizes the platform's focus on privacy and protection for users. However, specific details about its features or benefits are not provided.
Read more →-OSCR
Jan 13, 2026Oscar Health, Inc. 2025 Fourth Quarter and Full Year Earnings Conference Call
Oscar Health, Inc. will announce its fourth quarter and full year 2025 financial results on February 10, 2026. A conference call will follow at 8:00 AM ET to discuss these results. The call will be archived for 90 days on the company's investor relations website. Oscar Health continues to focus on technology-driven healthcare solutions.
Read more →-OSCR
Sep 16, 2025Oscar Health, Inc. News Release Oscar Health Prices Upsized $355,000,000 Convertible Senior Subordinated Notes Offering to Scale Long-Term Growth and Consumer and Employer Adoption of the Individual Market - Net proceeds
Oscar Health, Inc. has priced its upsized offering of $355 million in convertible senior subordinated notes, intended to bolster long-term growth and market adoption. The offering's net proceeds, estimated at approximately $342.5 million, will be used for corporate purposes and strategic initiatives. Notably, Oscar aims to enhance consumer healthcare experiences while pursuing opportunities related to premium tax credits.
Read more →-OSCR
Sep 15, 2025Oscar Health, Inc. News Release Oscar Health Launches Proposed Convertible Senior Subordinated Notes Offering to Scale Long-Term Growth and Consumer and Employer Adoption of the Individual Market Net proceeds to support
Oscar Health, Inc. has announced a proposed offering of $350 million in convertible senior subordinated notes, intending to use the proceeds for general corporate purposes and strategic growth initiatives. This initiative aims to enhance consumer healthcare experiences through advancements in AI and potentially extend premium tax credits. The company also plans to settle conversions with cash or shares of its common stock. The notes will be unsecured and subject to various conditions that could affect their performance and the company’s stock price.
Read more →-OSCR
Nov 20, 2023▲ +8.8%on this news
Oscar Health, Inc. ir.hioscar.com News Release Oscar Health, Inc. Announces that Mark Bertolini s Foundation and Deerfield Management have Entered into an Agreement with a Selling Shareholder to Purchase Shares of Oscar
Oscar Health, Inc. announced a Stock Purchase Agreement where Deerfield Management and the Anahata Foundation will purchase shares of its Common Stock. Deerfield is to acquire 3 million shares while Anahata will buy 2 million shares. The transactions are scheduled to close around November 22, 2023, pending customary conditions. Oscar is not a party to these agreements but benefits from the endorsement and financial backing of these investors.
Read more →-OSCR
Jan 27, 2022Oscar Health, Inc. ir.hioscar.com News Release Oscar Health Delivers Historic Growth, Issues Guidance for 2022 of More than $6B in Premiums Total enrollment for 2022 tops one million members across the Oscar platform Pro
Oscar Health Delivers Historic Growth, Issues Guidance for 2022 of More than $6B in Premiums NEW YORK, New York, January 27, 2022 Oscar Health, Inc. ( Oscar or the Company ) (NYSE: OSCR), the first health insurance company built on a full stack technology platform, today issued
Read more →Competitive Position
How OSCR ranks across every disease it competes inCompetitive Position is a premium feature
See how OSCR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial